Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I watched the video from Gartner. His message was just an attempt to con some money out of speculators. He cannot "market" any medical device to detect cancer. It is a clear violation of the FDA laws.
What he can do is provide the chemicals to labs in various states where the test can be "home brewed". Maybe it is only supposedly going to be available in 23 states because the lab he is attempting to deal with only has labs in the 23 states.
Also, Gartner has been attempting to raise this $l.5 million for many months now. Also, Gartner may in fact be well aware that this attempt will be a non success but in the mean time, he will have put a substantial amount of the $1.5 million directly in his pocket. It is just the way they do business.
Yes, as far as BioCurex is concerned, yes it is dead. The company is no longer is business and the last trading appeared to be someone interested in the shell. There may be a reverse merger in the future with another company.
There does not appear to be any mix up at all. What you have is a legal document that has signatures. If Mac was attempting to get some kind of royalties based on sales, it did not happen. In a legal document, what you see is what you get period. There are no hidden royalties.
I have been reading on filing chapter 7 prior to the lawsuit going to trial and it will create a "stay". Then the court has to decide what to do with Mac's portion of the lawsuit. Not sure what will happen but you can bet that Radient will file chapter prior to the trial date.
At that point, UNI will have total control of DR-70 and when the last patent expires next June, UNI has it all with no more royalties.
All the buzz on the forums about a merger entity is all just a dream by the bagholders. Once DR-70 is gone, there is nothing left of Radient.
dcspka, the tier change has nothing to do with the SEC. The pink sheet stocks are run by "OTC Markets Group Inc", and they made the tier change because Radient filed an 8K.
I don't think there is any reason why Radient would file bankruptcy. They cannot file a chapter 11 for lack of a lender so the option of the court converting to a chapter 7 will not happen.
However, there is the option of a creditor filing the chapter 7 for Radient in an attempt to get any remaining assets. The result of the class action lawsuit could end up with a chapter 7 to get assets.
One other item. If Mac is obligated to pay money as a result of the lawsuit, he CANNOT escape the obligation by filing personal bankruptcy. Debts due to crimminal acts cannot be discharged via a chapter 7 filing. IMO, Mac will lose his shirt on this one and any money from UNI will go to the lawyers defending Mac.
Since the sales of DR-70 are almost exclusive to SE Asia, this should tell you that Radient expects to cease production of the product at the Tustin facility.
This is just Mac selling off the last bit of value from Onko Sure. He attempted to sell off the production technology to GCDX and now is attempting to sell it off to UNI. Note that Radient only gets $20,000 until a successful commercial-scale production trial run is made by UNI manufacturing DR-70.
"The total fee for UNI’s five year Onko-Sure DR-70 license is five hundred thousand dollars ($500,000) USD to be paid out annually as per Paragraph 1.2 in Exhibit B below. UNI shall pay up-front (the “Up-Front License Fee) one hundred thousand dollars ($100,000) to RXPC in two installments: twenty thousand USD ($20,000) will be wired upon co-signing of the License Agreement with the remaining eighty thousand ($80,000) to be wired to RXPC after tech transfer training and commercial-scale trial-run production for Onko-Sure (DR-70) from RXPC. This License Agreement will become effective upon receipt of the up-front license fee to RXPC. "
Lakeshore, good points. In addition, there is a clause where there are no more royalties paid to Radient after the expiration of the last patent. That patent expires in Jun 2014. At that point, Radient is out of the picture.
"This Agreement shall become effective upon the date of signing by both Parties and continue in effect until the earlier to occur of: (i) expiration of the last patent issued to RXPC for the Licensed Products"
That's it folks. Uni got the "know how" to manufacture the test and will only have to pay the up front fee and it is all theirs. So, it the current patent application is not approve by June of next year, the agreement is terminated and the approval of that application is doubtful.
The bid is slowly going away. In a few weeks, you are likely to see a "no bid" situation again.
His phone lines still have the taped message about closing "some" of their facilities. Since he is continuing to pay for those phone lines, I still wonder what he is up to and will hang around if he attempts another scam startup.
Also, whoever bought all those shares owns close to 50% of the stock but they did not file a form 13 with the SEC.
Their information came from a tainted source...Radient.
If you do not believe Radient told lies, just look at the resume for the head of their Oncology from 2010 to 2012.
"Director, Clinical & Scientific Writing/editing (Immunogene Therapy, Oncology)
Radient Pharmaceuticals Corp., Tustin, CA, USA May 2010–Apr 2012
•Lead writer/translator for 5 protocols, 5 CSRs, 5 CSS, 5 CSE, 5 CSO, 1 IND, 1 NDA
•Lead writer/translator for 23 slide decks, 6 posters, 9 abstracts, 2 manuscripts, 2 CME
•Sourced, hired and managed 3 internal and 8 external medical writers/editors
•Directed/executed clinical trials related to company’s oncology products
•Presented clinical trial data at 6 conferences, 5 exhibitions and 10 meetings
•Drafted/QCed 5 case reports, and updated/maintained study databases and pipeline drug compendia/dossier"
No IND's nor any NDA was ever submitted.
No clinical trials were ever run by Radient during this period.
If you do not believe Radient told lies, just look at the resume for the head of their Oncology from 2010 to 2012.
"Director, Clinical & Scientific Writing/editing (Immunogene Therapy, Oncology)
Radient Pharmaceuticals Corp., Tustin, CA, USA May 2010–Apr 2012
•Lead writer/translator for 5 protocols, 5 CSRs, 5 CSS, 5 CSE, 5 CSO, 1 IND, 1 NDA
•Lead writer/translator for 23 slide decks, 6 posters, 9 abstracts, 2 manuscripts, 2 CME
•Sourced, hired and managed 3 internal and 8 external medical writers/editors
•Directed/executed clinical trials related to company’s oncology products
•Presented clinical trial data at 6 conferences, 5 exhibitions and 10 meetings
•Drafted/QCed 5 case reports, and updated/maintained study databases and pipeline drug compendia/dossier"
No IND's nor any NDA was ever submitted.
No clinical trials were ever run by Radient during this period.
If you do not believe Radient told lies, just look at the resume for the head of their Oncology from 2010 to 2012.
"Director, Clinical & Scientific Writing/editing (Immunogene Therapy, Oncology)
Radient Pharmaceuticals Corp., Tustin, CA, USA May 2010–Apr 2012
•Lead writer/translator for 5 protocols, 5 CSRs, 5 CSS, 5 CSE, 5 CSO, 1 IND, 1 NDA
•Lead writer/translator for 23 slide decks, 6 posters, 9 abstracts, 2 manuscripts, 2 CME
•Sourced, hired and managed 3 internal and 8 external medical writers/editors
•Directed/executed clinical trials related to company’s oncology products
•Presented clinical trial data at 6 conferences, 5 exhibitions and 10 meetings
•Drafted/QCed 5 case reports, and updated/maintained study databases and pipeline drug compendia/dossier"
No IND's nor any NDA was ever submitted.
No clinical trials were ever run by Radient during this period.
Blackpantherz, you are citing a quote from Radient about Onko Sure. Radient would like for you to believe it is an early detection test but it is NOT.
Absolutely NOWHERE in the FDA documention where AMDL applied for clearance or in the trials that were run does Radient claim it is an early detection test.
Later, when attempting to sell the test, Radient the hyped the term early detection which was clearly NOT an outcome of the clinical trials.
Blackpantherz, if you continue to only obtain your information about DR-70 from Radient sources, your knowledge about the test will be limited and incorrect.
http://www.radient-pharma.com/products/onkosure.php
Again, your quote came directly from Radient. If Radient was an honest company, it would be different but they are not.
Blackpantherz, DR-70 is not an early detection test for colorectal cancer. It is a test that is FDA cleared to monitor existing cases of CRC.
DR-70 has way too many false positives to be an early detection test.
It also tests positive for heart conditions, Infections, intestional disorders of any sort and several other conditions. If you want to read about the false positives, just check the AMDL application to the FDA where Radient excluded anyone with a condition that would give a false positive from participation in the trials. That is called "cooking the results".
Blackpantherz obviously does not understand the basic type of test that DR-70 is.
The article is discussing a better method of testing stool samples for the presence of blood.
If an investor does not know the difference between a stool sample and a blood sample, mutual funds would definitely be a more appropriate investment.
bioCurex used to be on the below website but it looks like Moro is not even attempting to sell the product out of his garage.
http://www.butlerschein.com/home/featured-vendors/vendor-partners
How can you not see the definition of Online only publications? It is right at the top of the page.
"Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2013 Annual Meeting but not presented at the Meeting, can be found online only.
Abstract No:
e22061
http://abstracts2.asco.org/AbstView_132_113941.html
My wife has a Go Daddy website and the domain name is in Scottsdale. The domain name is where the Go Daddy server is.
Now that's funny. You are now making a claim because Go Daddy is a company based in Scottsdale, AZ, that it has something to do with Onko Sure?
Here is the address of Go Daddy.
Corporate Headquarters. 14455 N. Hayden Rd., Ste. 226. Scottsdale, AZ 85260 (480) 505-8800.
Yep, that's proof that Go Daddy is now supporting Onko Sure.
Got anymore straws to reach for?
A post from Lakeshore.
"DR-70 abstract is not being presented at ASCO.
It is misleading to say that the DR-70 abstract is "at the upcoming ASCO meeting." It is NOT. It is a publication-only document.
The authors submitted the abstract to ASCO but ASCO did not select it for presentation. every abstract submitted is avaliable as a "publication-only" document, available online only. There are 4500 of them, including the DR-70 abstract.
So this abstract is NOT "at ASCO."
Furthermore. this abstract is for GI cancer, not lung cancer, so don't say it is linked to Provista or GCDx or William Gartner.
And the "takeover group" did not pay for the research, so this abstract is NOT proof that there is a takeover group. My wife writes for journals and presents at conferences -- she is paid by her University for her research and nobody else. That is how research works."
There are other studies listed also including those previously advertised by Radient where there were better results. Many studies on DR-70 have been made over the years but none of the studies seem to have persuaded the medical community to adopt the usage of DR-70 in the detection of cancer.
http://www.ncbi.nlm.nih.gov/pubmed/?term=dr-70
Again, another study.
Abstract
The aim of this study was to discover the clinical value of the tumour marker AMDL DR-70 in a group of patients with cancer of the tongue. Serum concentrations of AMDL DR-70 were estimated by enzyme linked immuno-sorbent assay in 52 patients with carcinoma of the tongue and compared with 40 controls and 42 patients with benign lesions in the tongue. Thirty-nine patients with carcinoma of the tongue had results above 6 mg/L (75%), compared with 3/40 (7%) in healthy controls and 4/42 (10%) in those with benign tumours. The concentration of AMDL DR-70 in serum correlated significantly with 3-year survival.
http://www.ncbi.nlm.nih.gov/pubmed/16188352
From the above, you can calculate the sensitivity and specificity.
Senstivity = 39 / 52 = 75%
Specificity for those having tumors 83%
for general screening, you would have 10% of all healthy people testing positive. That would be a HUGE number considering the incidence of cancer in the tounge is very low.
Another study.
CONCLUSION:
Both the SELDI-detected fragment of fibrinogen and DR-70 are significantly elevated in the serum of pancreatic cancer patients. However, they do not seem to improve pancreatic cancer detection over CA19-9 alone.
http://www.ncbi.nlm.nih.gov/pubmed/20555269
RESULTS:
Class prediction models based on CEA, DR-70 and sCD26 produced a modest increase in detection accuracy over CEA alone, particularly for early stage cancers. The sensitivity and specificity required for a clinically useful test was not reached.
CONCLUSION:
It is unlikely that a biomarker panel comprised of the currently available serum markers will generate a clinically useful diagnostic test for colorectal cancer. Our findings reiterate the urgent need to discover novel biomarkers for the detection of colorectal cancer.
http://www.ncbi.nlm.nih.gov/pubmed/21263188
Many here fail to understand the reasons why Lakeshore and my self post on this board.
I have been stating that this stock is worthless for the past 3 years. I am not working for anyone and certainly not buying the stock. If you want another example, I also posted on the BOCX board that their stock was also worthless for the past 4 years. It just takes a long time for things to finally bottom out the the company finally folds. I have received several thank yous for my posting on BOCX and sorrows that they did not believe me at the time and lost their money. The same foolish claims were made on that board that my postings were made for profit of some sort as they are made on this board.
Radient is just what Lakeshore states. It is a company with a failed product that no one will pay any significant money for and they also have a very toxic debt. That toxic debt makes the shell worthless also.
Jimtash, if you think the Patent application and trademark are so all important, what will happen when the lenders max out the share authorization and seize assets. Are the entities you keep referring to going to buy the patent application and pay the lenders their $18+ million to get it?
You just don't seem to understand. There is nothing in the new applcation specific to lung cancer nor any combination with other markers. It is just another attempt to extend the same old DR-70 patent. Just read the patent claims and enlighten yourself.
I think they will be awarded damages from MacLellan. That is why they asked for a jury trial. Juries don't follow the logic you are presenting. They will see Mac lying and that is what will stand out. Mac lied a lot and thet is why he ceased after the lawsuit was filed.
Sport stated: "If you base it off of the last rejection it looks like it takes about 4 months."
If you look at the history of the patent application and look at the claims, There is NOTHING about a combination of markers of any sort.
There is nothing about lung cancer. This just claims a method of monitoring cancer as well as restating claims from previous patents.
There has been no re-examination of the application. It received a final rejection in August 2012. A response was requested within 3 months. No response was made but an extension was requested.
In Feb 2013, a response to the rejection was submitted and a phone call was made to the examiner. The examiner then agreed to withdraw the final rejection and docket the application for re-examination.
That is the history of the application and re-examinations typically take more than 24 months.
"Docketed New Case - Ready for Examination
Status Date:
02-20-2013"
Nothing is going to happen anytime soon and there is NOTHING that GCDX or anyone else would be waiting for in this patent.
Sport stated: "If someone has a test kit that detects cancer in the early stages it's hard for that product to fail"
Onko Sure was cleared by the FDA to monitor CRC in June 2008. It detects 13 types of cancer as claimed by Radient. It has failed in this second marketing attempt. The first lab to sign a distribution agreement in the USA in 2009 dropped the product for lack of sales. Genway has now also dropped the product for USA distribution.
If you think it is hard for this product to fail, why then has it failed? Are you wrong?
The following was a judgement rendered in the case of a CEO lying to customers. I certainly think the same could be applied to MacLellan lying to shareholders buying stock. MacLellan has a lot to worry about with this lawsuit.
"On Friday, October 29, 2010, the court entered a civil verdict against Heidi Diaz for fraud and false advertising. Some had hoped she would be held criminally liable for the damage she inflicted on so many people by serving time in jail for what she had done. But the judgment against her wasn’t a cakewalk either:
- $1,824,210.39 in restitution to class members
- $500,000 in punitive damages
- Attorney fees dating back to 2007
- A temporary restraining order freezing all of her assets
- Not allowed to contact, harass or cyberbully the plaintiffs or witnesses against her"
The following are more lies told by MacLellan. The government program to sell Onko Sure in India was a scam.
http://money.cnn.com/news/newsfeeds/articles/marketwire/0674596.htm
Snizzle, a 68 cent trade moved the share price to .0002 just like a small trade will move the price back down on Monday.
Lakeshore is absolutely correct. Radient has had 5 years since DR-70 was FDA cleared and still, no significant market exists.
MacLellan has lied about studies making claims that were not true.
One other fact to remember, the only independent study done by combining DR-70 used two additional markers and that study concluded that the combination was not specific enough to be used for screening. If you just listen to all the claims made by Radient, the test should be selling like hot cakes but anyone with any savvy at all understands the real facts.
It is clear that the party interested in the shell wants a majority position. He has almost a million shares so he needs about 300,000 more to control the company. If he pays 10 cents a share, it will cost him another $30,000.
At this point, if I had shares, I would not be selling them. Whatever he is going to do with the company, the shares will be worth more than 10 cents.
The main lender is currently owed about $750,000 and Asher is owed about $40,000. When the new owner of the shell takes over, those debts still have to be resolved so it would appear that the total cost of the shell and control will add up to about a million bucks.
This is certainly interesting to see what he is going to do with the shell.
None of todays trades were unresolved so the shares are coming from the open market and not Asher. A total of 835,000 shares traded so the buyers for the shell got 1/3 of the company today.
I now know for a fact there is interest in the shell. Maybe Moro is shopping the shell.
I notice today that huge buying is going on for BOCX. After a 1 for 150 reverse split, there are just over 2.5 million shares so a third of the company was purchased today. They should have to file ownership forms with the SEC within a few days.
This is not for BioCurex but for the shell. The company has closed their lab, shut down the websites and the lender has foreclosed.
For a fact, there is interest in the shell.
This interesting. Someone wants control of the company and they now have 1/3 of the OS shares. They have spent about $25,000 in doing so. That appears to be a cheap way to buy an active shell.
In the past, the new owners of the shell would reverse split the stock to get rid of shareholders but now all reverse splits have to be approved by FINRA so that might be difficult.
I wonder how much more the buyer is willing to spend. Another 500k shares and he has a majority share position.